Expert comment: Understanding the new EMA variation requirements

Long-awaited variation updates

The recently updated EMA variation requirements reflect a major revision of both the legal framework and its practical guidance. It is essential to understand the distinct roles of the legally binding Variation Regulation and the accompanying EMA Variation Guideline, as well as the key drivers behind their revision and the practical implications for regulatory submissions.

The EMA Variation Regulation (EC) 1234/2008, concerning variations to marketing authorisations for medicines, is the legally binding EU law defining the variation procedure and the types of changes allowed. The significantly amended (EU) 2024/1701 became applicable on January 1, 2025.

In contrast, the new EMA Variation Guideline C/2025/5045 published September 22, 2025, provides detailed instructions on how to apply the regulation and clarifies documentation requirements and classification categories. It has likewise been through an extensive update to reflect the revision of the regulation and will apply to all new variations submitted from January 15, 2026.

Drivers behind the revision

The previous Variation Guideline was introduced in 2013, and since then, the pharmaceutical landscape has evolved considerably, with significant scientific advances in drug development, improvements in pharmaceutical technology, and substantial regulatory progress.

One notable example is the coronavirus pandemic which significantly influenced the regulatory approach to vaccines and accelerated approval processes to address for urgent public health needs.

Furthermore, the EU Medical Device Regulation (EU) 2017/745 (EU MDR) entered into force on 25 May 2017, replacing earlier directives to strengthen the safety and quality of medical devices placed on the European market. The MDR introduces stricter requirements, enhanced post-market surveillance, and mandatory unique device identification (UDI) for devices like pacemakers, software, and even certain aesthetic products. 

A third example is the handling of design space, which is now better understood by both companies and the Competent Authorities, and can generally be submitted as a minor variation.

Together, these developments and many more have played an important role in shaping the new variation guidelines.

Key updates in the guideline

1. Categories and classification

• Revised variation categories: the previous A (administrative), B (quality), C (safety/efficacy/pharmacovigilance), and D (specific changes to Plasma Master Files and Vaccine Antigen Master Files) are now E, Q, C, and M, respectively.
• Detailed justification is now required for unclassified Type II variations.
• Safety-related Type II variations must be implemented immediately.
• References to veterinary products have been removed.

2. Submission procedure

• Annual bundling of Type IA variations is now allowed through super-grouping or an annual report.
• Mandatory work-sharing for minor Type IB variations affecting multiple marketing authorisations (CP, DCP/MR, National) is required.
• From January 2025, all variations (including extensions) must be submitted via the IRIS digital platform.
• The guideline emphasizes flexibility in managing minor variations and improved coordination across multiple marketing authorisations owned by the same MAH.

3. Tools and documentation

• Introduction of new tools: Post-Approval Change Management Protocol (PACMP) for pre-agreed change pathways and the Product Lifecycle Management Document (PLCM) for ongoing MA oversight.
• Detailed documentation requirements for changes to active substances, excipients, or medical device components.
• Emergency update flexibility is provided for human vaccines addressing public health emergencies in the EU.

Considerations and implications for industry

The improvements in the new variation guideline are evident, with the introduction and procedural guidance sections simplified and updated to reflect current practice. Additionally, the requirements and documentation for various types of changes are now clearly defined, reducing the risk of misinterpretations.

The streamlined approach of the new guideline requires mandatory grouping of minor changes of Type IA, while the work-sharing procedure for Type IB is expected to enhance the effectiveness of assessments by the Competent Authorities, without altering the overall timeline.

The corresponding updates to the EU Electronic Application Form (eAF) eAF v.1.28.0.0 for submission via the IRIS portal are expected to make the submission and the related process smoother, addressing some of the difficulties encountered with the current eAF.

Furthermore, the introduction of new regulatory guidelines may cause some confusion during the transition period and give rise to numerous questions. Thus, it is recommended to consult the guidance provided by the EMA and the CMDh. The published official Q&A documents are also helpful for clarifying areas that are not fully addressed in the guidance.